This is my first appeal. Any feedback welcome, and if it is helpful for anyone, please leverage!
UnitedHealthcare Appeals Unit
P.O. Box 30575
Salt Lake City, UT 84130-0575
Fax: (801) 938-2100
APPEAL REQUEST
Service Ref # XXXXXXXXXXXX
Specific Coverage Decision being appealed: Clinical evidence in published peer-reviewed medical literature is insufficient to show that a gastric sleeve procedure by itself is a safe and effective treatment for morbid obesity, thus is an unproven procedure and not covered by benefits.
I am requesting an appeal of this decision based on the following:
The UnitedHealthcare Bariatric Surgery Medical Policy document approval date is 12/20/2007, and the papers referenced with respect to Laparascopic Sleeve Gastrectomy (LSG) policy are all from January 2007sleep apnea, and the best surgical procedure for me, supported by current peer-reviewed literature, is the vertical sleeve gastrectomy.
Supporting Literature
A systematic review of the literature covering LSG through January 2009[6] was published in June this year. Conclusion: From the current evidence, including 36 studies and 2570 patients, LSG is an effective weight loss procedure that can be performed safely as a first stage or primary procedure. From this large volume of case series data, a matched cohort analysis, and 2 randomized trials, LSG results in excellent weight loss and co-morbidity reduction that exceeds, or is comparable to, that of other accepted bariatric procedures. The postoperative major complication rates and mortality rates have been acceptably low. Long-term data are limited, but the 3- and 5-year follow-up data have demonstrated the durability of the SG procedure.
A handful of additional work has been published since that literature review concluded, with additional long term durability data and adding considerable support to the efficacy of LSG in resolving diabetes.[7],[8],[9],[10],[11],[12],[13]
Since the UHC bariatric surgery policy was written, two International Consensus Summits for Sleeve Gastrectomy have been held, the first[14] 10/25-27/2007 and the second[15] 3/19-21/2009. At the second conference, during the consensus part, the audience responded that there was enough evidence published to support the use of SG as a primary procedure to treat morbid obesity and indicated that it is on par with adjustable gastric banding and Roux-en-Y gastric bypass, with a yes vote at 77%.
Conclusion
Supporting references have been provided which demonstrate Laparoscopic Sleeve Gastrectomy as an effective, durable and proven surgical procedure for the treatment of morbid obesity and associated co-morbidities. Given my long term dependence on steroids, LSG is the best option for me to treat my morbid obesity and associated diabetes, sleep apnea and high blood pressure. I request coverage be granted for the laparoscopic sleeve gastrectomy procedure.
Sincerely,
xxxxxx xxxxxxxx (Name deleted for privacy purposes)
encl
References
[1] ECRI. Custom Hotline Response. Laparoscopic Sleeve Gastrectomy (LSG) for Morbid Obesity. March 2006. Updated January 2007, referenced in the UnitedHealth Care Bariatric Surgery Medical Policy 12/20/2007.
[2] The incidence of a marginal ulcer perforating after Laparoscopic Roux-n-Y Gastric Bypass was significant (>1%) and appeared to be related to smoking or the use of NSAIDs or steroids: E.L. Felix EL, Kettelle J, Mobley E, Swartz D, Perforated marginal ulcers after laparoscopic gastic bypass, Surgical Endoscopy,2008, 22(10): 2128-2132.
[3] The Lap-Band System is not approved for people on long-term steroid replacement (LAP-BAND System Information for Patients, pg 6 - Contraindications, Allergan, Inc., 2007) http://www.lapband.c...ntraindications
[4] The Realize Personalized Banding Solution is contraindicated for those on long term steroid therapy (Ethicon Endo-Surgery website, patient information) http://www.realize.c...siderations.htm.
[5] VGB procedures are essentially no longer performed. Medicare National Coverage Determinations Manual, Chapter 1, Part 2 (Sections 90 160.26): Coverage Determinations
[6] Brethauer S, Hammel J, Schauer P, Systematic review of sleeve gastrectomy as staging and primary bariatric procedure, Surg Obes Relat Dis. 2009, 5(4): 469-475.
[7] Rosenthal R, Li X, Samuel S, Martinez P, Zheng C, Effect of sleeve gastrectomy on patients with diabetes mellitus, Surg Obes Relat Dis. 2009, 5(4): 429-434
[8] Fuks D, Verhaeghe P, Brehant O, et al. Results of laparoscopic sleeve gastrectomy: A prospective study in 135 patients with morbid obesity. Surgery. 2009;145(1): 106113.
[9] Peterli, R, Improvement in Glucose Metabolism after Bariatric Surgery: Comparison of Laparoscopic Roux-en-Y Gastric Bypass and Laparoscopic Sleeve Gastrectomy. Annals of Surgery 250(2): 2009
[10] Court I, Bellorin O, Dip F, DuCoin C, Szomstein S, Rosenthal RJ, Evolution of Sleeve Gastrectomy as a primary procedure for weight loss in morbid obesity, Bariatric Times 2009 5(5).
[11] Arias E, Martnez PR, Li VKM, Szomstein S, Rosenthal RJ, Mid-term Follow-up after Sleeve Gastrectomy as a Final Approach for Morbid Obesity. Obes Surg. 2009 19(5): 544-548
[12] Eid G, Mattar S, Patel S, Gourash W, McCloskey C, Ramanathan R, Schauer P. Laparoscopic sleeve gastrectomy: 5 year follow-up. Surg Obes Relat Dis. 2009 5(3): S5
[13] Todkar J, Shah S, Shah P, Gangwani J, Weight loss & evolution of co-morbidities & quality of life following sleeve gastrectomy for morbid obesity with type 2 diabetes mellitus: Results at more than 3 years Surg Obes Relat Dis. 2009, 5(3): S52-S53.
[14] Deitel M, Crosby RD, Gagner M. The First International Consensus Summit for Sleeve Gastrectomy (SG), New York City, October 2527, 2007. Obes Surg. 2008,18(5):487496
[15] Gagner M, Deitel M, Kalberer T, Erickson A, Crosby R. The Second International Consensus Summit for Sleeve Gastrectomy, Miami Beach, FL, March 1921, 2009, Surg Obes Relat Dis. 2009, 5(4): 476-485.